The effects of the DRD2 polymorphism on smoking cessation and negative affect: Evidence for a pharmacogenetic effect on mood

Paul M. Cinciripini, David W. Wetter, Gail E. Tomlinson, Janice Y. Tsoh, Carl A. De Moor, Lynn G. Cinciripini, John D. Minna, Walter S. Baile

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

This study evaluated the relationship between smoking cessation treatment outcome and the DRD2 polymorphism. Participants were 134 smokers who took part in a larger clinical trial evaluating the effects of an antidepressant medication (venlafaxine or placebo) plus standard care (brief counseling and nicotine replacement therapy). Venlafaxine is an antidepressant that inhibits the reuptake of serotonin and norepinephrine. A1 smokers were expected to quit significantly less often on placebo, although the abstinence rates between A1s and A2s on active drug were not expected to differ (i.e., an interaction between genotype and drug was hypothesized). In addition, antidepressant therapy was expected to have a similar genotype × treatment interaction on negative affect reduction. The results showed that smokers carrying the DRD2 A1 allele (A1/A1/A2) quit significantly less often than the homozygous A2s (OR=1.54, 95% CI=1.01-2.36). No interaction with treatment was observed. A significant pharmacogenetic effect of the drug on negative mood while quitting also was noted. Smokers absent the A1 allele (A2/A2) responded to the drug with a substantial reduction in negative affect, whereas those with the A1 allele showed no significant reduction in negative mood, F(1, 130) = 5.95, p =.01. These results are contrary to expectations and suggest that although A1s may have more difficulty quitting, adding venlafaxine does not improve abstinence or mood. However, the results for the A2s provide evidence for a genotype-specific response to a pharmacological intervention, which could have implications for the development of future treatments.

Original languageEnglish (US)
Pages (from-to)229-239
Number of pages11
JournalNicotine and Tobacco Research
Volume6
Issue number2
DOIs
StatePublished - Apr 2004

Fingerprint

Pharmacogenetics
Smoking Cessation
varespladib methyl
Antidepressive Agents
Alleles
Genotype
Pharmaceutical Preparations
Placebos
Therapeutics
Withholding Treatment
Nicotine
Counseling
Serotonin
Norepinephrine
Clinical Trials
Pharmacology
Venlafaxine Hydrochloride

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Cinciripini, P. M., Wetter, D. W., Tomlinson, G. E., Tsoh, J. Y., De Moor, C. A., Cinciripini, L. G., ... Baile, W. S. (2004). The effects of the DRD2 polymorphism on smoking cessation and negative affect: Evidence for a pharmacogenetic effect on mood. Nicotine and Tobacco Research, 6(2), 229-239. https://doi.org/10.1080/14622200410001676396

The effects of the DRD2 polymorphism on smoking cessation and negative affect : Evidence for a pharmacogenetic effect on mood. / Cinciripini, Paul M.; Wetter, David W.; Tomlinson, Gail E.; Tsoh, Janice Y.; De Moor, Carl A.; Cinciripini, Lynn G.; Minna, John D.; Baile, Walter S.

In: Nicotine and Tobacco Research, Vol. 6, No. 2, 04.2004, p. 229-239.

Research output: Contribution to journalArticle

Cinciripini, Paul M. ; Wetter, David W. ; Tomlinson, Gail E. ; Tsoh, Janice Y. ; De Moor, Carl A. ; Cinciripini, Lynn G. ; Minna, John D. ; Baile, Walter S. / The effects of the DRD2 polymorphism on smoking cessation and negative affect : Evidence for a pharmacogenetic effect on mood. In: Nicotine and Tobacco Research. 2004 ; Vol. 6, No. 2. pp. 229-239.
@article{be8212ae6d2641f1b24c613904faa24d,
title = "The effects of the DRD2 polymorphism on smoking cessation and negative affect: Evidence for a pharmacogenetic effect on mood",
abstract = "This study evaluated the relationship between smoking cessation treatment outcome and the DRD2 polymorphism. Participants were 134 smokers who took part in a larger clinical trial evaluating the effects of an antidepressant medication (venlafaxine or placebo) plus standard care (brief counseling and nicotine replacement therapy). Venlafaxine is an antidepressant that inhibits the reuptake of serotonin and norepinephrine. A1 smokers were expected to quit significantly less often on placebo, although the abstinence rates between A1s and A2s on active drug were not expected to differ (i.e., an interaction between genotype and drug was hypothesized). In addition, antidepressant therapy was expected to have a similar genotype × treatment interaction on negative affect reduction. The results showed that smokers carrying the DRD2 A1 allele (A1/A1/A2) quit significantly less often than the homozygous A2s (OR=1.54, 95{\%} CI=1.01-2.36). No interaction with treatment was observed. A significant pharmacogenetic effect of the drug on negative mood while quitting also was noted. Smokers absent the A1 allele (A2/A2) responded to the drug with a substantial reduction in negative affect, whereas those with the A1 allele showed no significant reduction in negative mood, F(1, 130) = 5.95, p =.01. These results are contrary to expectations and suggest that although A1s may have more difficulty quitting, adding venlafaxine does not improve abstinence or mood. However, the results for the A2s provide evidence for a genotype-specific response to a pharmacological intervention, which could have implications for the development of future treatments.",
author = "Cinciripini, {Paul M.} and Wetter, {David W.} and Tomlinson, {Gail E.} and Tsoh, {Janice Y.} and {De Moor}, {Carl A.} and Cinciripini, {Lynn G.} and Minna, {John D.} and Baile, {Walter S.}",
year = "2004",
month = "4",
doi = "10.1080/14622200410001676396",
language = "English (US)",
volume = "6",
pages = "229--239",
journal = "Nicotine and Tobacco Research",
issn = "1462-2203",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - The effects of the DRD2 polymorphism on smoking cessation and negative affect

T2 - Evidence for a pharmacogenetic effect on mood

AU - Cinciripini, Paul M.

AU - Wetter, David W.

AU - Tomlinson, Gail E.

AU - Tsoh, Janice Y.

AU - De Moor, Carl A.

AU - Cinciripini, Lynn G.

AU - Minna, John D.

AU - Baile, Walter S.

PY - 2004/4

Y1 - 2004/4

N2 - This study evaluated the relationship between smoking cessation treatment outcome and the DRD2 polymorphism. Participants were 134 smokers who took part in a larger clinical trial evaluating the effects of an antidepressant medication (venlafaxine or placebo) plus standard care (brief counseling and nicotine replacement therapy). Venlafaxine is an antidepressant that inhibits the reuptake of serotonin and norepinephrine. A1 smokers were expected to quit significantly less often on placebo, although the abstinence rates between A1s and A2s on active drug were not expected to differ (i.e., an interaction between genotype and drug was hypothesized). In addition, antidepressant therapy was expected to have a similar genotype × treatment interaction on negative affect reduction. The results showed that smokers carrying the DRD2 A1 allele (A1/A1/A2) quit significantly less often than the homozygous A2s (OR=1.54, 95% CI=1.01-2.36). No interaction with treatment was observed. A significant pharmacogenetic effect of the drug on negative mood while quitting also was noted. Smokers absent the A1 allele (A2/A2) responded to the drug with a substantial reduction in negative affect, whereas those with the A1 allele showed no significant reduction in negative mood, F(1, 130) = 5.95, p =.01. These results are contrary to expectations and suggest that although A1s may have more difficulty quitting, adding venlafaxine does not improve abstinence or mood. However, the results for the A2s provide evidence for a genotype-specific response to a pharmacological intervention, which could have implications for the development of future treatments.

AB - This study evaluated the relationship between smoking cessation treatment outcome and the DRD2 polymorphism. Participants were 134 smokers who took part in a larger clinical trial evaluating the effects of an antidepressant medication (venlafaxine or placebo) plus standard care (brief counseling and nicotine replacement therapy). Venlafaxine is an antidepressant that inhibits the reuptake of serotonin and norepinephrine. A1 smokers were expected to quit significantly less often on placebo, although the abstinence rates between A1s and A2s on active drug were not expected to differ (i.e., an interaction between genotype and drug was hypothesized). In addition, antidepressant therapy was expected to have a similar genotype × treatment interaction on negative affect reduction. The results showed that smokers carrying the DRD2 A1 allele (A1/A1/A2) quit significantly less often than the homozygous A2s (OR=1.54, 95% CI=1.01-2.36). No interaction with treatment was observed. A significant pharmacogenetic effect of the drug on negative mood while quitting also was noted. Smokers absent the A1 allele (A2/A2) responded to the drug with a substantial reduction in negative affect, whereas those with the A1 allele showed no significant reduction in negative mood, F(1, 130) = 5.95, p =.01. These results are contrary to expectations and suggest that although A1s may have more difficulty quitting, adding venlafaxine does not improve abstinence or mood. However, the results for the A2s provide evidence for a genotype-specific response to a pharmacological intervention, which could have implications for the development of future treatments.

UR - http://www.scopus.com/inward/record.url?scp=2542495997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542495997&partnerID=8YFLogxK

U2 - 10.1080/14622200410001676396

DO - 10.1080/14622200410001676396

M3 - Article

C2 - 15203796

AN - SCOPUS:2542495997

VL - 6

SP - 229

EP - 239

JO - Nicotine and Tobacco Research

JF - Nicotine and Tobacco Research

SN - 1462-2203

IS - 2

ER -